FDA-grade engineering for clinical and commercial systems

The Part 11 compliance failure mode in pharmaceutical technology is predictable: a software team builds a capable clinical or manufacturing system, the regulatory affairs team identifies Part 11 as a requirement late in the project, and the validation exercise reveals that the architecture does not support the required audit trail, the access control model doesn't satisfy individual accountability requirements, and the electronic signature implementation doesn't meet FDA's definition. Retrofit validation is expensive — typically three to five times the cost of building compliant from the start — and often requires system changes that delay go-live by six to twelve months. In the clinical trial context, delays translate directly to extended development timelines and increased study costs. In manufacturing, delays affect product launch schedules and create gap periods in production documentation that FDA inspectors will scrutinize. The data integrity failures that produce FDA warning letters are almost always architectural — systems that allow record modification without audit trail capture, shared accounts that prevent individual accountability, and time stamp implementations that are not reliable because they depend on client-side clocks.

The Algorithm designs pharmaceutical systems with validation as the organizing principle of the architecture. The audit trail is not a feature added after the core functionality is built — it is the foundation on which the application logic sits. Every record creation, modification, or deletion event generates a tamper-evident audit entry with the user identity, timestamp, reason for change, and previous value. Access controls are implemented with role-based permissions tied to individual user accounts, with no shared credentials at any system level. Electronic signature workflows satisfy the two-component identification requirement for Part 11 signatories. The validation documentation package — Installation Qualification, Operational Qualification, Performance Qualification, and User Requirements Specification — is produced as a byproduct of the build process, not as a retroactive documentation exercise. GAMP 5 category classification is determined at the architecture phase, and the validation strategy is designed proportionate to the software category. The result is a system that enters the FDA inspection environment with a complete evidence package and a validation state that has been maintained through every change.

Healthcare — Pharmaceuticals & Life Sciences Compliance Assessment

A structured checklist for evaluating your AI and software vendor's readiness across the key regulatory frameworks in Healthcare. Free — no email required.